Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Nov;72(5):1270–1277. doi: 10.1038/bjc.1995.499

Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.

W K Evans 1, B P Will 1, J M Berthelot 1, M C Wolfson 1
PMCID: PMC2033927  PMID: 7577481

Abstract

Escalating health care costs have made it imperative to evaluate the resources required to diagnose and treat major illnesses in Canadians. For Canadian men, lung cancer is not only the most common malignancy, but also the major cancer killer. As of 1994, lung cancer is expected to overtake breast cancer as the leading cause of cancer deaths in women. This paper presents a detailed description of the methodology used to determine the direct health care costs associated with 'standard' diagnostic and therapeutic approaches for lung cancer in Canada in 1988. Clinical algorithms were developed for each stage of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The algorithms were designed to take the form of decision trees for each clinical stage of lung cancer. The proportion of patients assigned to each branch was based upon questionnaire responses obtained from thoracic surgeons and radiation oncologists when presented with clinical scenarios, and information from provincial cancer registries. Direct care costs were derived primarily from one provincial fee schedule (Ontario), and costing information obtained during the conduct of several Canadian clinical trials in lung cancer. Direct costs for diagnosis and initial treatment of NSCLC (excluding relapse and terminal care costs) ranged from $17,889 for the surgery/post-operative radiotherapy arm of stages I and II to $6,333 for the supportive care arm (stage IV). The cost of determining relapse for NSCLC was estimated to be $1,528, and terminal care costs, which included palliative radiotherapy and hospitalisation, were $10,331. Direct costs for diagnosis and initial treatment of SCLC ranged from $18,691 for limited stage disease to $4,739 for the supportive care arm of extensive disease. The cost of diagnosing relapse for SCLC was estimated to be $1,590, and terminal care costs averaged $9,966. This report provides an estimate of the Canadian costs of managing lung cancer by stage and treatment modality. Because the actual costs of all components of care are not available from any combination of sources, these cost estimates must be viewed as an idealised estimate of the cost of lung cancer management. However, we believe that the lung cancer costing model that we have developed provides a level of sophistication which gives a reasonable estimate of the cost per case of treating NSCLC and SCLC.

Full text

PDF
1273

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chu J., Diehr P., Feigl P., Glaefke G., Begg C., Glicksman A., Ford L. The effect of age on the care of women with breast cancer in community hospitals. J Gerontol. 1987 Mar;42(2):185–190. doi: 10.1093/geronj/42.2.185. [DOI] [PubMed] [Google Scholar]
  2. Duncan G., Duncan W., Maher E. J. Patterns of palliative radiotherapy in Canada. Clin Oncol (R Coll Radiol) 1993;5(2):92–97. doi: 10.1016/s0936-6555(05)80855-6. [DOI] [PubMed] [Google Scholar]
  3. Durrant K. R., Berry R. J., Ellis F., Ridehalgh F. R., Black J. M., Hamilton W. S. Comparison of treatment policies in inoperable bronchial carcinoma. Lancet. 1971 Apr 10;1(7702):715–719. doi: 10.1016/s0140-6736(71)91986-6. [DOI] [PubMed] [Google Scholar]
  4. Evans W. K., Feld R., Murray N., Willan A., Coy P., Osoba D., Shepherd F. A., Clark D. A., Levitt M., MacDonald A. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med. 1987 Oct;107(4):451–458. doi: 10.7326/0003-4819-107-4-451. [DOI] [PubMed] [Google Scholar]
  5. Feld R., Evans W. K., Coy P., Hodson I., MacDonald A. S., Osoba D., Payne D., Shelley W., Pater J. L. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol. 1987 Sep;5(9):1401–1409. doi: 10.1200/JCO.1987.5.9.1401. [DOI] [PubMed] [Google Scholar]
  6. Feld R., Evans W. K., DeBoer G., Quirt I. C., Shepherd F. A., Yeoh J. L., Pringle J. F., Payne D. G., Herman J. G., Chamberlain D. Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol. 1984 Apr;2(4):294–304. doi: 10.1200/JCO.1984.2.4.294. [DOI] [PubMed] [Google Scholar]
  7. Goodwin P. J., Feld R., Evans W. K., Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol. 1988 Oct;6(10):1537–1547. doi: 10.1200/JCO.1988.6.10.1537. [DOI] [PubMed] [Google Scholar]
  8. Guadagnoli E., Weitberg A., Mor V., Silliman R. A., Glicksman A. S., Cummings F. J. The influence of patient age on the diagnosis and treatment of lung and colorectal cancer. Arch Intern Med. 1990 Jul;150(7):1485–1490. [PubMed] [Google Scholar]
  9. Holmes E. C. Surgical adjuvant therapy of non-small-cell lung cancer. J Surg Oncol Suppl. 1989;1:26–33. doi: 10.1002/jso.2930420507. [DOI] [PubMed] [Google Scholar]
  10. Jaakkimainen L., Goodwin P. J., Pater J., Warde P., Murray N., Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol. 1990 Aug;8(8):1301–1309. doi: 10.1200/JCO.1990.8.8.1301. [DOI] [PubMed] [Google Scholar]
  11. Mackillop W. J., O'Sullivan B., Ward G. K. Non-small cell lung cancer: how oncologists want to be treated. Int J Radiat Oncol Biol Phys. 1987 Jun;13(6):929–934. doi: 10.1016/0360-3016(87)90109-x. [DOI] [PubMed] [Google Scholar]
  12. Maher E. J., Coia L., Duncan G., Lawton P. A. Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe. Int J Radiat Oncol Biol Phys. 1992;23(1):239–244. doi: 10.1016/0360-3016(92)90568-3. [DOI] [PubMed] [Google Scholar]
  13. Payne D. G. Non-small-cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy? J Clin Oncol. 1988 Mar;6(3):552–558. doi: 10.1200/JCO.1988.6.3.552. [DOI] [PubMed] [Google Scholar]
  14. Rapp E., Pater J. L., Willan A., Cormier Y., Murray N., Evans W. K., Hodson D. I., Clark D. A., Feld R., Arnold A. M. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633–641. doi: 10.1200/JCO.1988.6.4.633. [DOI] [PubMed] [Google Scholar]
  15. Samet J., Hunt W. C., Key C., Humble C. G., Goodwin J. S. Choice of cancer therapy varies with age of patient. JAMA. 1986 Jun 27;255(24):3385–3390. [PubMed] [Google Scholar]
  16. Shields T. W. Screening, diagnosis, and staging of non-small cell lung cancer and consideration of unusual primary tumors of the lungs. Curr Opin Oncol. 1992 Apr;4(2):299–307. doi: 10.1097/00001622-199204000-00011. [DOI] [PubMed] [Google Scholar]
  17. Silliman R. A., Guadagnoli E., Weitberg A. B., Mor V. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol. 1989 Mar;44(2):M46–M50. doi: 10.1093/geronj/44.2.m46. [DOI] [PubMed] [Google Scholar]
  18. Wodinsky H. B., Jenkin R. D. The cost of radiation treatment at an Ontario regional cancer centre. CMAJ. 1987 Nov 15;137(10):906–909. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES